Vevizye Eye

ApprovedSmall molecule

MMedical University of Vienna

Vevizye Eye is one of 38 small molecule programs targeting Eye Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseActive, not recruiting

Eye DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

2 2

Alphagan

AbbVie

Phase 3

2 3

Chantix

Pfizer

Phase 3

2 4

Bayer Aspirin

Bayer

Phase 3

1 5

Zovirax

BBp Consulting, Inc

Phase 3

2 6

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 7

CF101

CCan-Fite BioPharma

Phase 3

1 8

Carboxymethylcellulose

AbbVie

Phase 3

4 9

Vevizye Eye

MMedical University of Vienna

Approved

1 10

Refresh Plus

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Eye Disease

NCT07463950

Clinical

Trials by Indication[1]

Eye Disease1 trial

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

Recruiting·MMedical University of Vienna·Phase 4·NCT07463950·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vevizye Eye. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vevizye Eye compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vevizye Eye. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMedical University of Vienna

Vevizye Eye

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Eye Disease1 trial

References

Drug Info

Quick Facts

Related News